Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

GNLX

Genelux Corp

2.72

Aug 10 • 3:59 PM ET 0.00 (0.00%)

Healthcare Biotechnology USA Micro NASD

Peers: CNTB GALT IMUX IPHA KZIA SPRO VRCA VTVT AGEN ALPS

| Held by: VTI VXF IWC BTEC CHNA

Scroll to Statements

Index	-
Market Cap	121.97M
Enterprise Value	98.26M
Income	-33.58M
Sales	0.01M
Book/sh	0.51
Cash/sh	0.58
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	26
IPO	Jan 26, 2023

P/E	-
Forward P/E	-
PEG	-
P/S	12197.00
P/B	5.32
P/C	4.65
P/FCF	-
EV/EBITDA	-
EV/Sales	9826.00
Quick Ratio	3.68
Current Ratio	3.68
Debt/Eq	0.11
LT Debt/Eq	0.10
Option/Short	Yes / Yes

EPS (ttm)	-0.85
EPS next Y	-0.76
EPS next Q	-0.20
EPS this Y	5.23%
EPS next Y	6.50%
EPS next 5Y	46.39%
EPS past 3/5Y	-59.75% -8.40%
Sales past 3/5Y	-91.03% -
EPS Y/Y TTM	3.16%
Sales Y/Y TTM	0.00%
EPS Q/Q	5.73%
Sales Q/Q	-
Earnings	May 07 AMC
EPS/Sales Surpr.	-2.56% -

Insider Own	14.30%
Insider Trans	-0.72%
Inst Own	31.28%
Inst Trans	0.62%
ROA	-94.12%
ROE	-127.28%
ROIC	-133.79%
Gross Margin	-6562.50%
Oper. Margin	-432112.50%
Profit Margin	-419762.50%
SMA20	-4.90%
SMA50	-6.74%
SMA200	-21.19%
Trades

Shs Outstand	44.84M
Shs Float	38.43M
Short Float	8.10%
Short Ratio	15.38
Short Interest	3.11M
52W High	8.53 -68.13%
52W Low	2.29 18.78%
Volatility	9.91% 5.82%
ATR (14)	0.18
RSI (14)	44.34
Beta	0.54
Rel Volume	0.00
Avg Volume	202.42K
Volume	0

Perf Week	-8.72%
Perf Month	-10.23%
Perf Quarter	-12.54%
Perf Half Y	13.81%
Perf YTD	-37.61%
Perf Year	-13.65%
Perf 3Y	-89.85%
Perf 5Y	-
Perf 10Y	-
Recom	1.00
Target Price	17.50
Prev Close	2.72
Price	2.72
Change %	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-21-25	Initiated	Lake Street	Buy	$16
Oct-29-24	Initiated	Guggenheim	Buy	$8
Aug-28-24	Initiated	ROTH MKM	Buy	$10
Nov-27-23	Initiated	H.C. Wainwright	Buy	$35
Sep-12-23	Initiated	Maxim Group	Buy	$40
Feb-15-23	Initiated	The Benchmark Company	Speculative Buy	$10

Jun-30-26 08:00AM	Genelux Announces Publication of Translational Analysis Supporting Immune Activation and Chemotherapy Sensitization with Olvi-Vec in Ovarian Cancer (GlobeNewswire)
May-07-26 04:15PM	Genelux Corporation Reports First Quarter Financial Results and Provides Business Updates (GlobeNewswire) +9.89%
Mar-19-26 04:15PM	Genelux Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates (GlobeNewswire) -5.51%
Feb-18-26 08:00AM	Genelux Corporation to Participate in Upcoming Conferences (GlobeNewswire)
Jan-12-26 04:00PM	Genelux Corporation Announces Upcoming Virtual Fireside Chat Hosted by Titan Partners (GlobeNewswire) -5.36%
09:13AM	Loading…
Jan-08-26 09:13AM	Genelux Corporation Announces Pricing of $20.0 Million Underwritten Public Offering of Common Stock (GlobeNewswire) -19.76%
Jan-07-26 04:01PM	Genelux Corporation Announces Proposed Public Offering of Common Stock (GlobeNewswire)
Jan-05-26 08:00AM	Genelux Corporation Reports Encouraging Interim Data of Systemic Administration of Olvi-Vec in Ongoing Lung Cancer Trials (GlobeNewswire) -23.52%
Jan-02-26 08:00AM	Genelux Corporation Announces Appointment of Jason Litten, M.D., as Chief Medical Officer (GlobeNewswire)
Nov-26-25 08:00AM	Genelux Corporation to Participate in a Fireside Chat at Piper Sandler 37th Annual Healthcare Conference (GlobeNewswire) +5.67%
Nov-05-25 04:20PM	Genelux Corporation Reports Third Quarter 2025 Financial Results and Provides General Business Updates (GlobeNewswire) -32.40%
Sep-02-25 04:01PM	Genelux Corporation to Participate in a Fireside Chat at H.C. Wainwright Global Investment Conference (GlobeNewswire)
Aug-07-25 04:20PM	Genelux Corporation Reports Second Quarter 2025 Financial Results and Provides General Business Updates (GlobeNewswire) -6.96% -5.69%
Jul-07-25 07:00AM	Genelux Corporation Announces Appointment of Eric Groen as General Counsel, Corporate Secretary, Chief Compliance Officer and Head of Business Development (GlobeNewswire)
Jun-02-25 12:00PM	Genelux Corporation (GNLX) Upgraded to Buy: Here's What You Should Know (Zacks)
04:10PM	Loading…
May-06-25 04:10PM	Genelux Corporation Reports First Quarter 2025 Financial Results and Provides General Business Updates (GlobeNewswire) -7.17%
May-01-25 04:05PM	Genelux Corporation to Participate in a Fireside Chat at the Citizens Life Sciences Conference (GlobeNewswire) -9.85% +8.45%
Apr-18-25 09:40AM	Is EUROFINS SCIENT (ERFSF) Outperforming Other Medical Stocks This Year? (Zacks)
Mar-28-25 04:10PM	Genelux Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update (GlobeNewswire) -12.34%
09:35AM	Down -29.7% in 4 Weeks, Here's Why Genelux Corporation (GNLX) Looks Ripe for a Turnaround (Zacks)
Mar-25-25 08:31AM	Genelux Corporation Announces Pricing of $10.5 Million Underwritten Offering of Common Stock (GlobeNewswire) -12.60%
08:30AM	Genelux Announces Alignment with FDA on Key Elements of the Approval Pathway for Olvi-Vec in Platinum Resistant/Refractory Disease (GlobeNewswire)
08:30AM	Genelux and Newsoara Announce Positive Preliminary Phase 1b/2 Data of Olvi-Vec in Advanced Small-Cell Lung Cancer (GlobeNewswire)
Mar-02-25 09:39AM	Why Genelux Corporation (GNLX) is Skyrocketing So Far in 2025 (Insider Monkey)
Feb-03-25 06:45AM	Genelux Corporation Announces New Chief Financial Officer (GlobeNewswire) -10.63%
Dec-13-24 07:01AM	Genelux Corporation to Participate in a Fireside Chat with H.C. Wainwright (GlobeNewswire) -7.54%
Nov-15-24 09:50AM	These 2 Strong Buy Penny Stocks Are Set to Triple (or more), Say Analysts (TipRanks) -19.73%
Nov-14-24 04:05PM	Genelux Corporation Reports Third Quarter 2024 Financial Results and Provides General Business Updates (GlobeNewswire)
Nov-06-24 04:01PM	Genelux Corporation to Participate in Fireside Chat at the Guggenheim Inaugural Healthcare Innovation Conference (GlobeNewswire)
Oct-25-24 01:01PM	Highbridge Capital Management LLC Acquires Significant Stake in Genelux Corp (GuruFocus.com)
11:27AM	Loading…
Oct-23-24 11:27AM	Genelux doses first subject in Phase II trial of NSCLC treatment (Clinical Trials Arena)
Oct-22-24 04:01PM	Genelux Corporation Announces First Patient Dosed in Phase 2 Trial Evaluating Systemic Therapy with Olvi-Vec in Non-Small Cell Lung Cancer (GlobeNewswire)
Oct-09-24 04:15PM	Genelux Corporation to Participate in the 2024 Maxim Healthcare Virtual Summit (GlobeNewswire)
Sep-03-24 04:01PM	Genelux Corporation to Present at the H.C. Wainwright Global Investment Conference (GlobeNewswire) +13.94%
Aug-14-24 09:54PM	GNLX Stock Earnings: Genelux Beats EPS for Q2 2024 (InvestorPlace)
04:05PM	Genelux Corporation Reports Second Quarter 2024 Financial Results and Provides General Business Updates (GlobeNewswire)
Aug-12-24 05:16PM	Genelux Corporation (GNLX): A Strong Buy According to Hedge Funds (Insider Monkey) -6.57%
Jul-30-24 07:00AM	Genelux Corporation to Participate in Fireside Chat at BTIG's Virtual Biotechnology Conference 2024 (GlobeNewswire)
May-24-24 08:00AM	Genelux Corporation Announces Pricing of Approximately $27.5 Million Underwritten Offering of Common Stock and Accompanying Warrants (GlobeNewswire) -43.04%
May-23-24 04:01PM	Genelux Corporation Announces Proposed Public Offering of Common Stock and Warrants (GlobeNewswire) -5.35%
May-09-24 11:53PM	GNLX Stock Earnings: Genelux Misses EPS for Q1 2024 (InvestorPlace) +6.07%
04:25PM	Genelux Corporation Reports First Quarter 2024 Financial Results and Provides General Business Updates (GlobeNewswire)
Apr-26-24 09:35AM	Down -48.37% in 4 Weeks, Here's Why Genelux Corporation (GNLX) Looks Ripe for a Turnaround (Zacks)
Apr-23-24 09:35AM	Down -45.44% in 4 Weeks, Here's Why Genelux Corporation (GNLX) Looks Ripe for a Turnaround (Zacks)
Apr-05-24 09:35AM	After Plunging -26.21% in 4 Weeks, Here's Why the Trend Might Reverse for Genelux Corporation (GNLX) (Zacks)
Apr-04-24 12:00PM	All You Need to Know About Genelux Corporation (GNLX) Rating Upgrade to Buy (Zacks)
Apr-02-24 07:52AM	GNLX Stock Earnings: Genelux Misses EPS for Q4 2023 (InvestorPlace)
Apr-01-24 07:00AM	Genelux Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire) -18.51%
Dec-15-23 03:01PM	Insider Sell Alert: Director James Tyree Offloads 9,000 Shares of Genelux Corp (GNLX) (GuruFocus.com) -13.23%
Nov-27-23 07:00AM	Genelux Corporation Receives FDA Fast Track Designation for Olvi-Vec in Platinum Resistant/Refractory Ovarian Cancer (GlobeNewswire)
Nov-14-23 05:50PM	Genelux Corporation Reports Third Quarter 2023 Financial Results and Provides General Business Updates (GlobeNewswire) -7.61%
Oct-20-23 01:22PM	12 Best Performing Biotech Stocks in 2023 (Insider Monkey)
Oct-11-23 09:00AM	Young Adults and Pancreatic Cancer: What the 80% Rise in Diagnoses Means for Future Treatment (PR Newswire)
Sep-19-23 03:01PM	Director John Thomas Sells 6667 Shares of Genelux Corp (GNLX) (GuruFocus.com) +8.04%
Sep-15-23 03:03PM	Director John Smither Sells 900 Shares of Genelux Corp (GNLX) (GuruFocus.com)
Sep-14-23 01:21PM	10% Owner Aladar Szalay Sells 52,616 Shares of Genelux Corp (GNLX) (GuruFocus.com)
07:00AM	Genelux Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-07-23 04:01PM	Genelux Corporation to Present at the H.C. Wainwright Global Investment Conference (GlobeNewswire) -6.69%
Aug-28-23 07:00AM	Genelux Corporation Announces New Chief Financial Officer (GlobeNewswire) +11.01%
Aug-14-23 07:00AM	Genelux Corporation Reports Second Quarter 2023 Financial Results and Provides General Business Updates (GlobeNewswire)
Aug-02-23 04:00PM	Genelux Corporation to Participate in Fireside Chat at BTIGs Virtual Biotechnology Conference 2023 (GlobeNewswire) +5.52%
01:08AM	10 Recent IPOs in 2023 to Consider (Insider Monkey)
Jul-28-23 10:54AM	Why Shares of Genelux Climbed This Week (Motley Fool) -9.38%
Jul-20-23 04:45PM	Genelux Corporation Strengthens Senior Management and Clinical Team with Promotions and New Hires (GlobeNewswire) -10.85% -15.77%
Jul-10-23 07:00AM	Genelux Corporation Announces Publication of Phase I Trial Results of Intrapleural Administration of Olvi-Vec in Patients with Malignant Pleural Effusion from Mesothelioma, Lung or Breast Cancers in Frontiers in Immunology (GlobeNewswire)
Jun-29-23 07:00AM	Genelux Corporation and TVAX Biomedical, Inc. announce the issuance of a United States patent covering the combination of an adoptive T cell therapy/oncolytic viral cancer treatment that is exclusively licensed to V2ACT Therapeutics, LLC (GlobeNewswire)
Jun-22-23 07:00AM	Genelux Corporation Set to Join the Russell 3000® and Russell 2000® Indexes Effective June 26, 2023 (GlobeNewswire) -7.05%
Jun-12-23 07:00AM	Genelux Corporation Announces $18 Million Private Placement (GlobeNewswire) +7.58%
Jun-01-23 05:19PM	Why Shares of Genelux Corporation Jumped This Week (Motley Fool) +6.62%
May-25-23 04:01PM	Genelux Corporation Announces Publication of Positive Topline Data from Phase 2 VIRO-15 Trial Evaluating Olvimulogene Nanivacirepvec (Olvi-Vec) in Platinum-Resistant or Refractory Ovarian Cancer in the Journal of the American Medical Association (JAMA) Oncology (GlobeNewswire) +6.62%
May-15-23 07:00AM	Genelux Corporation Announces $33 Million Private Placement (GlobeNewswire) -9.06%
Mar-23-23 07:00AM	Genelux Corporation to Ring Nasdaq Opening Bell on March 29, 2023 (GlobeNewswire)
Jan-25-23 09:00PM	Genelux Corporation Announces Pricing of Initial Public Offering (GlobeNewswire)

Genelux Corp. manufactures and markets drugs and virus strains solutions. It provides drug research, development, and clinical trial services for the healthcare industry. The company was founded by Aladar Szalay on September 4, 2001 and is headquartered in Westlake Village, CA.

ChairmanMr. Thomas D. Zindrick J.D.

CFO and Principal Financial & Accounting OfficerMr. Matthew Pulisic M.B.A.

Chief Technical OfficerDr. Joseph Cappello Ph.D.

Chief Scientific OfficerDr. Yong Yu Ph.D.

General CounselMr. Eric Groen J.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Yu Yong	Chief Scientific Officer	Aug 04 '26	Sale	2.94	653	1,922	268,371	Aug 04 08:20 PM
Cappello Joseph	Chief Technical Officer	Aug 04 '26	Sale	2.95	653	1,924	328,737	Aug 04 08:20 PM
Zindrick Thomas	President and CEO	Aug 04 '26	Sale	2.95	3,023	8,905	1,260,890	Aug 04 08:20 PM
Smither John W	Director	Jul 01 '26	Sale	2.91	12,000	34,898	91,403	Jul 02 04:35 PM
JOHN SMITHER	Director	Jul 01 '26	Proposed Sale	2.91	12,000	34,898		Jul 01 06:16 PM
Smalling Ralph	Head of Regulatory	Jun 03 '26	Sale	2.93	192	563	67,611	Jun 04 08:35 PM
Thomas John	Director	Jun 01 '26	Sale	2.98	10,000	29,801	472,784	Jun 02 08:35 PM
JOHNNY THOMAS	Officer	Jun 01 '26	Proposed Sale	3.05	10,000	30,500		Jun 01 04:32 PM
Yu Yong	Chief Scientific Officer	May 11 '26	Sale	2.97	605	1,798	149,706	May 12 08:30 PM
Cappello Joseph	Chief Technical Officer	May 11 '26	Sale	2.97	605	1,799	154,549	May 12 08:30 PM
Zindrick Thomas	President and CEO	May 11 '26	Sale	2.94	2,798	8,226	532,051	May 12 08:30 PM
Smalling Ralph	Head of Regulatory	May 11 '26	Sale	2.98	270	804	67,803	May 12 08:30 PM
Smalling Ralph	Head of Regulatory	Mar 24 '26	Sale	2.42	345	835	68,313	Mar 26 05:00 PM
Smalling Ralph	Head of Regulatory	Mar 25 '26	Sale	2.51	240	602	68,073	Mar 26 05:00 PM
Cappello Joseph	Chief Technical Officer	Mar 24 '26	Sale	2.42	906	2,193	155,154	Mar 26 05:00 PM
Yu Yong	SVP, Clinical Development	Mar 24 '26	Sale	2.42	906	2,193	144,938	Mar 26 05:00 PM
Zindrick Thomas	President and CEO	Mar 24 '26	Sale	2.42	3,582	8,668	534,849	Mar 26 05:00 PM
Thomas John	Director	Mar 02 '26	Sale	2.90	10,000	28,957	482,784	Mar 03 08:05 PM
JOHNNY THOMAS	Officer	Mar 02 '26	Proposed Sale	2.98	10,000	29,800		Mar 02 04:32 PM
Yu Yong	SVP, Clinical Development	Aug 21 '25	Sale	3.36	3,219	10,807	146,817	Dec 11 08:50 PM
Yu Yong	SVP, Clinical Development	Nov 17 '25	Sale	5.37	973	5,224	145,844	Dec 11 08:50 PM
Zindrick Thomas	President and CEO	Aug 21 '25	Sale	3.33	12,673	42,159	542,940	Dec 11 08:50 PM
Zindrick Thomas	President and CEO	Nov 17 '25	Sale	5.37	4,509	24,211	538,431	Dec 11 08:50 PM
Cappello Joseph	Chief Technical Officer	Aug 21 '25	Sale	3.34	2,733	9,137	157,033	Dec 11 08:49 PM
Cappello Joseph	Chief Technical Officer	Nov 17 '25	Sale	5.37	973	5,224	156,060	Dec 11 08:49 PM
Smalling Ralph	Head of Regulatory	Aug 21 '25	Sale	3.36	1,244	4,177	69,746	Dec 09 08:00 PM
Smalling Ralph	Head of Regulatory	Sep 03 '25	Sale	3.36	580	1,948	69,166	Dec 09 08:00 PM
Smalling Ralph	Head of Regulatory	Nov 17 '25	Sale	5.37	343	1,842	68,823	Dec 09 08:00 PM
Smalling Ralph	Head of Regulatory	Dec 05 '25	Sale	4.69	165	774	68,658	Dec 09 08:00 PM
Thomas John	Director	Dec 01 '25	Sale	5.00	10,000	50,008	492,784	Dec 02 07:00 PM
JOHNNY THOMAS	Director	Dec 01 '25	Proposed Sale	5.56	10,000	55,600		Dec 01 04:34 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

GNLX

Genelux Corp

Upgrade your Finviz experience